Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$368.42 USD

368.42
284,333

+10.23 (2.86%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 57.03% and 2.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

What to Expect From These 3 MedTech Stocks This Earnings Season

Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?

FitLife Brands (FTLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.

National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.

Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure

Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered

Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.

Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 46.70% and 1.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

What's in Store for These 4 MedTech Stocks in Q2 Earnings?

Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.

All You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy

Bio-Rad (BIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.

Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.

Phibro (PAHC) Down 3.3% Since Last Earnings Report: Can It Rebound?

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down

Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 12.25% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for April 19th

ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.

Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?

The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.